In addition, five prostate cancer–associated genes (EGF, PIK3R1, ATM, BRCA1, and BRCA2) with apparent damaging mutations, one of which is a rare mutation in ATM, a possible therapeutic target, further support this claim. This evidence concerns the gene BRCA2 and prostate carcinoma.